<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        12-665-17
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZOFRAN 2MG\ML INJECTION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ONDANSETRON
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Ampoule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        120.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLAXOSMITHKLINE (GSK)" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLAXOSMITHKLINE (GSK)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 439]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Novartis Saudi Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            NOVARTIS PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A04AA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zofran injection contains a medicine called ondansetron. This belongs to a group of medicines called anti-emetics.</p><p>&nbsp;</p><p>Zofran injection is used for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preventing nausea and vomiting caused by chemotherapy (in adults and children) or radiotherapy for cancer (adults only)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; preventing nausea and vomiting after surgery.</p><p>&nbsp;</p><p>Ask your doctor, nurse or pharmacist if you would like any further explanation about these uses.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>D</strong><strong>o not have Zofran injection if:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking apomorphine (used to treat Parkinson&rsquo;s disease)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic (hypersensitive) to ondansetron or any of the other ingredients in Zofran injection (listed in Section 6).</p><p>If you are not sure, talk to your doctor, nurse or pharmacist before having Zofran injection.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Check with your doctor, nurse or pharmacist before having Zofran injection if:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had heart problems (e.g. congestive heart failure which causes shortness of breath and swollen ankles)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an uneven heart beat (arrhythmias)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to medicines similar to ondansetron, such as granisetron or palonosetron</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have liver problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have a blockage in your gut</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have problems with the levels of salts in your blood, such as potassium, sodium and magnesium.</p><p>If you are not sure if any of the above apply to you, talk to your doctor, nurse or pharmacist before having Zofran injection.</p><p>&nbsp;</p><p><strong>Ot</strong><strong>her medicines and Zofran</strong></p><p>Please tell your doctor, nurse or pharmacist if you are taking, or have recently taken, or might take any other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because Zofran can affect the way some medicines work. Also some other medicines can affect the way Zofran works.</p><p>&nbsp;</p><p>In particular, tell your doctor, nurse or pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbamazepine or phenytoin used to treat epilepsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin used to treat infections such as tuberculosis (TB)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; antibiotics such as erythromycin or ketoconazole</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anti-arrhythmic medicines used to treat an uneven heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; beta-blocker medicines used to treat certain heart or eye problems, anxiety or prevent migraines</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tramadol, a pain killer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines that affect the heart (such as haloperidol or methadone)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cancer medicines (especially anthracyclines and trastuzumab).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SSRIs (selective serotonin reuptake inhibitors) used to treat depression and/or anxiety including fluoxetine, paroxetine, sertraline, fluvoxamine, citalopram, escitalopram</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SNRIs (serotonin noradrenaline reuptake inhibitors) used to treat depression and/or anxiety including venlafaxine, duloxetine</p><p>&nbsp;</p><p>If you are not sure if any of the above applies to you, talk to your doctor, nurse or pharmacist before having Zofran injection.</p><p>&nbsp;</p><p>Zofran injection should not be given in the same syringe or infusion (drip) as any other medication.</p><p>&nbsp;</p><p><strong>P</strong><strong>regnancy and breast-feeding</strong></p><p>Only use during the first trimester of pregnancy after discussion with your doctor of the potential benefits and risks to you and your unborn baby of the different treatment options.&nbsp; This is because Zofran can slightly increase the risk of a baby being born with cleft lip and/or cleft palate (openings or splits in the upper lip and/or the roof of the mouth). &nbsp;If you are already pregnant, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before having Zofran. If you are a woman of childbearing potential you may be advised to use effective contraception.</p><p>&nbsp;</p><p>Do not breast-feed if you have Zofran. This is because small amounts pass into the mother&rsquo;s</p><p>milk. Ask your doctor or midwife for advice.</p><p>&nbsp;</p><p><strong>I</strong><strong>mportant information about some of the ingredients of Zofran injection</strong></p><p>This medicine contains sodium citrate and sodium chloride. This means that Zofran injection contains 7 mg of sodium per 4 mg dose, which is less than 1 mmol sodium (23 mg) per dose i.e. essentially &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zofran injection is normally given by a nurse or doctor. The dose you have been prescribed will depend on the treatment you are having.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>T</strong><strong>o prevent nausea and vomiting from chemotherapy or radiotherapy in adults</strong></p><p>&nbsp;</p><p>On the day of chemotherapy or radiotherapy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the usual adult dose is 8 mg given by a slow injection into your vein or muscle, just before your treatment, and another 8 mg twelve hours later. &nbsp;After chemotherapy, your medicine will usually be given by mouth as an 8 mg Zofran tablet or 10 ml (8 mg) Zofran syrup.</p><p>&nbsp;</p><p>On the following days</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the usual adult dose is one 8 mg tablet or 10 ml (8 mg) syrup taken twice a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; this may be given for up to 5 days.</p><p>&nbsp;</p><p>If your chemotherapy or radiotherapy is likely to cause severe nausea and vomiting, you may be given more than the usual dose of Zofran. Your doctor will decide this.</p><p>&nbsp;</p><p><strong>T</strong><strong>o prevent nausea and vomiting from chemotherapy in children aged over 6 months and adolescents</strong></p><p>&nbsp;</p><p>The doctor will decide the dose depending on the child&rsquo;s size (body surface area) or weight. Look at the label for more information</p><p>&nbsp;</p><p>On the day of chemotherapy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the first dose is given by an injection into the vein, just before your child&rsquo;s treatment. After chemotherapy, your child&rsquo;s medicine will usually be given by mouth twelve hours later, as Zofran syrup or a Zofran tablet.</p><p>&nbsp;</p><p>On the following days</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.5 ml (2 mg) syrup twice a day for small children and those weighing 10 kg or less</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; one 4 mg tablet or 5 ml (4 mg) syrup twice a day for larger children and those weighing more than 10 kg</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; two 4 mg tablets or 10 ml (8 mg) syrup twice a day for teenagers (or those with a large body surface area)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; these doses can be given for up to five days</p><p>&nbsp;</p><p><strong>T</strong><strong>o prevent and treat nausea and vomiting after an operation</strong></p><p>&nbsp;</p><p>Adult:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The usual dose for adults is 4 mg given by a slow injection into your vein or an injection into your muscle. For prevention, this will be given just before your operation.</p><p>&nbsp;</p><p>Children:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For children aged over 1 month and adolescents the doctor will decide the dose. The maximum dose is 4 mg given as a slow injection into the vein. For prevention, this will be given just before the operation.</p><p>&nbsp;</p><p><strong>P</strong><strong>atients with moderate or severe liver problems</strong></p><p>The total daily dose should not be more than 8 mg.</p><p>&nbsp;</p><p><strong>I</strong><strong>f you keep feeling or being sick</strong></p><p>Zofran injection should start to work soon after having the injection. If you continue to be sick or feel sick, tell your doctor or nurse.</p><p>&nbsp;</p><p><strong>I</strong><strong>f you have more Zofran injection than you should</strong></p><p>Your doctor or nurse will give you or your child Zofran injection so it is unlikely that you or your child will receive too much. If you think you or your child have been given too much or have missed a dose, tell your doctor or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Zofran injection can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>A</strong><strong>ll</strong><strong>ergic reactions</strong></p><p>If you have an allergic reaction, tell your doctor or a member of the medical staff straight away. The signs may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sudden wheezing and chest pain or chest tightness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swelling of your eyelids, face, lips, mouth or tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash - red spots or lumps under your skin (hives) anywhere on your body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; collapse.</p><p>&nbsp;</p><p><strong>Ot</strong><strong>her side effects include:</strong></p><p>&nbsp;</p><p><strong>V</strong><strong>ery common (may affect more than 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache.</p><p>&nbsp;</p><p><strong>C</strong><strong>ommon (may affect up to 1 in 10 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a feeling of warmth or flushing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; changes to liver function test results (if you have Zofran injection with a medicine called cisplatin, otherwise this side effect is uncommon)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irritation and redness at the site of injection.</p><p>&nbsp;</p><p><strong>U</strong><strong>ncommon (may affect up to 1 in 100 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hiccups</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood pressure, which can make you feel faint or dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; uneven heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; unusual body movements or shaking.</p><p>&nbsp;</p><p><strong>R</strong><strong>are (may affect up to 1 in 1,000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy or light headed</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blurred vision</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disturbance in heart rhythm (sometimes causing a sudden loss of consciousness)</p><p>&nbsp;</p><p><strong>V</strong><strong>ery rare (may affect up to 1 in 10,000 people)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; poor vision or temporary loss of eyesight, which usually comes back within 20 minutes.</p><p>&nbsp;</p><p><strong>R</strong><strong>eporting of side effects</strong></p><p>If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.</p><p>&nbsp;</p><p>By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep this medicine out of the sight and reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use Zofran injection after the expiry date which is stated on the pack after &lsquo;EXP&rsquo;. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store Zofran injection below 30&deg;C. Protect from light.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; When Zofran injection is diluted in intravenous fluids:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it must be stored at 2-8&deg;C for not more than 24 hours</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; it does not need to be protected from light during infusion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p><strong>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>What Zofran injection contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active ingredient is ondansetron. Each 2 ml Zofran injection ampoule contains ondansetron 4 mg. Each 4 ml Zofran injection ampoule contains ondansetron 8 mg.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are citric acid (E330), sodium citrate (E331), sodium chloride and Water for Injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Zofran injection is a clear, colourless liquid. Zofran injection is available in:
•	2 ml (4 mg) glass ampoules 
•	4 ml (8 mg) glass ampoules 

Packed in boxes of 5 ampoules. Not all packs are marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>The Marketing Authorization Holder for this Product is Novartis Pharma.</strong></p><p><strong>www.Novartis.com</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 09/2020 by MHRA.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي عقار زوفران للحقن على دواء يُسمى أوندانسيترون. ينتمي هذا الدَّواء إلى مجموعة من الأدوية تسمى مضادات القيء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُستَخدَم عقار زوفران للحقن للأغراض الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من الغثيان والقيء الناجمين عن تلقي العلاج الكيميائي (في البالغين والأطفال) أو العلاج الإشعاعي لمرض السرطان (البالغون فقط)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوقاية من الغثيان والقيء بعد إجراء العمليات الجراحية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">استشر طبيبك أو الممرض(ة) أو الصيدلي إذا كنت تود الحصول على أي شرح إضافي بشأن هذه الاستخدامات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتلقى العلاج بعقار زوفران للحقن في الحالات الآتية</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول آبومُورْفين (دواء يُستَخدَم لعلاج مرض الشلل الرعَّاش [مرض باركنسون]).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من الحساسية (الحساسية المفرطة) تجاه أوندانسيترون أو أيٍّ من المكونات الأخرى الموجودة بعقار زوفران للحقن (المُدرَجة في قسم: 6).</p><p dir="RTL">إذا لم تكن متأكدًا، تحدَّث مع طبيبك أو الممرض(ة) أو الصيدلي قبل تلقي العلاج بعقار زوفران للحقن.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">راجع طبيبك أو الممرض(ة) أو الصيدلي قبل تلقي الحَقْن بعقار زوفران في الحالات الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد عانيت من قبل من مشاكل في القلب (على سبيل المثال: فشل القلب الاحتقاني الذي يُسبب ضيقًا في التَّنفُّس وتورُّمًا في الكاحلين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من عدم انتظام ضربات القلب (اضطرابات النَّظْم القلبي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من حساسية تجاه الأدوية المشابهة لأوندانسيترون، مثل: جرانيسيترون أو بالونوسيترون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مشاكل بالكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من انسداد في الأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تُعاني من مشاكل في مستويات الأملاح في الدَّم، مثل: البوتاسيوم والصوديوم والماغنسيوم.</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان ينطبق عليك أيٌّ مما سبق، فتحدَّث مع طبيبك أو الممرض(ة) أو الصيدلي قبل تلقي الحَقن بعقار زوفران.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناوُل أدوية أخرى مع عقار زوفران</strong></p><p dir="RTL">يُرجى إخبار طبيبك، الممرض(ة) أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أيَّة أدوية أخرى. يتضمن ذلك الأدوية التي تقوم بشرائها بدون وصفة طبية وكذلك الأدوية العشبية. ذلك لأن عقار زوفران قد يؤثر على طريقة عمل بعض الأدوية. كذلك قد تؤثر بعض الأدوية الأخرى على طريقة عمل عقار زوفران.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، أخبر طبيبك أو الممرض(ة) أو الصيدلي إذا كنت تتناول أيًّا من الأدوية الآتية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كَرْبامازِيبين أو فينيتوين اللذين يُستَخدَمان لعلاج الصَّرع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين، وهو دواء يُستَخدَم لعلاج العدوى مثل السُّل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية مثل: إريثروميسين أو كيتوكونازول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المضادة لاضطرابات النظم القلبي، والتي تُستَخدَم لعلاج عدم انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حاصرات بيتا التي تُستَخدَم لعلاج بعض مشاكل القلب أو العين أو القلق أو لمنع حدوث الصداع النصفي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ترامادول، وهو أحد مُسَكِّنات الألم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤثر على القلب (مثل: هالُوبِيرِيدُول أو ميثادون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية السرطان (لا سيَّما الأنثراسيكلينات وتراستوزوماب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إعادة امتصاص السيروتونين الانتقائية التي تُستَخدَم لعلاج الاكتئاب و/أو القلق، وتشمل: فلوكسيتين، باروكسيتين، سيرترالين، فلوفوكسامين، سيتالوبرام، إسيتالوبرام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات إعادة امتصاص السيروتونين-النورإيبينفرين التي تُستَخدَم لعلاج الاكتئاب و/أو القلق، وتشمل فينلافاكسين، دولوكسيتين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان ينطبق عليك أيٌّ مما سبق، فتحدَّث مع طبيبك أو الممرض(ة) أو الصيدلي قبل تلقي الحَقن بعقار زوفران.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عدم إعطاء عقار زوفران للحقن في نفس السرنجة أو وعاء التَّسريب (التَّنقيط) كما هو الحال مع أي علاج آخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا تستخدمي العقار أثناء الثُّلث الأول من الحَمْل إلا بعد إجراء مناقشة مع طبيبكِ بشأن الفوائد والمخاطر المُحتَمَلة لخيارات العلاج المختلفة عليكِ وعلى جنينكِ.&nbsp; ذلك لأن عقار زوفران قد يؤدي إلى حدوث زيادة طفيفة في خطر إصابة الطفل المولود بانشقاق الشفة و/أو الحنك المشقوق (فتحات أو شقوق في الشفة العليا و/أو سقف الفم).&nbsp; إذا كنتِ حاملًا بالفعل، أو تعتقدين أنكِ قد تكونين حاملًا أو تخططين لذلك، فاستشيري طبيبكِ أو الصيدلي الخاص بكِ قبل تلقي عقار زوفران. إذا كنتِ سيدة ولديكِ القدرة على الحَمْل، فقد تُسدى إليكِ المشورة لاستخدام وسيلة فعَّالة لمنع الحَمْل.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تمارسي الرضاعة الطبيعية إذا كنتِ تتلقين عقار زوفران. ذلك نظرًا لمرور كميات قليلة منه إلى لبن الأم.</p><p dir="RTL">&nbsp;استشيري طبيبكِ أو قابلتكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات عقار زوفران للحقن</strong></p><p dir="RTL">يحتوي هذا الدَّواء على سترات الصوديوم وكلوريد الصوديوم. هذا يعني أن عقار زوفران للحقن يحتوي على 7 مجم من الصوديوم في كل جرعة قدرها 4 مجم، وهو ما يقل عن 1 مللي مول من الصوديوم (23 مجم) لكل جرعة، أي أنه &quot;خالي من الصوديوم&quot; بشكل أساسي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">عادةً يتولى الطبيب أو الممرض(ة) إعطاء عقار زوفران للحقن. ستعتمد الجرعة الموصوفة لك على العلاج الذي تتلقاه.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للوقاية من الغثيان والقيء الناجمين عن تلقي العلاج الكيميائي أو العلاج الإشعاعي في البالغين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">في يوم تلقي العلاج الكيميائي أو العلاج الإشعاعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المُعتادة للبالغين 8 مجم تُعطى عن طريق الحَقْن البطيء في الوريد أو العضل، قبل علاجك مباشرةً، و8 مجم أخرى بعد اثنتي عشرة ساعة.&nbsp; بعد تلقي العلاج الكيميائي، سيُعطى دواؤك عادةً عن طريق الفم بمقدار 8 مجم من عقار زوفران أقراص أو 10 مللي لترات (8 مجم) من عقار زوفران شراب.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأيام التَّالية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المُعتادة للبالغين قرصًا واحدًا 8 مجم أو 10 مللي لترات (8 مجم) شراب مرّتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تُعطى هذه الجرعة لمدة تصل إلى 5 أيام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان من المُرَجَّح أن يُسبب لك العلاج الكيميائي أو العلاج الإشعاعي غثيانًا وقيئًا شديدًا، فقد يتم إعطاؤك جرعة أكبر من الجرعة المعتادة من عقار زوفران. سيقرر طبيبك ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للوقاية من الغثيان والقيء الناجمين عن تلقي العلاج الكيميائي في الأطفال ممن تزيد أعمارهم عن </strong><strong>6 </strong><strong>أشهر والمراهقين</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">سيحدد الطبيب الجرعة وفقًا لحجم الطفل (مساحة سطح الجسم) أو وزنه. ألق نظرة على المُلصَق للاطلاع على المزيد من المعلومات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في يوم تلقي العلاج الكيميائي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تُعطى الجرعة الأولى عن طريق الحَقْن في الوريد، قبل علاج طفلك مباشرةً. بعد تلقي العلاج الكيميائي، سيُعطى طفلك الدَّواء عادةً عن طريق الفم بعد اثنتي عشرة ساعة، بعقار زوفران شراب أو عقار زوفران أقراص.</p><p dir="RTL">&nbsp;</p><p dir="RTL">في الأيام التَّالية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.5 مللي لتر (2 مجم) شراب مرّتين في اليوم للأطفال الصغار وأولئك الذين تبلغ أوزانهم 10 كجم أو أقل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرص واحد قدره 4 مجم أو شراب بمقدار 5 مللي لترات (4 مجم) مرّتين في اليوم للأطفال الأكبر وأولئك الذين تزيد أوزانهم عن 10 كجم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرصان قدر كل منهما 4 مجم أو شراب بمقدار 10 مللي لترات (8 مجم) مرّتين في اليوم للمراهقين (أو ممن لديهم مساحة سطح جسم كبيرة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُمكِن إعطاء هذه الجرعات لمدة تصل إلى خمسة أيام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للوقاية من الغثيان والقيء بعد إجراء العمليات الجراحية وعلاجهما</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">البالغون:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تبلغ الجرعة المعتادة للبالغين 4 مجم تُعطى عن طريق الحَقْن البطيء في الوريد أو الحَقْن في العضل. لأغراض الوقاية، ستُعطى هذه الجرعة قبل إجراء العملية الجراحية مباشرةً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأطفال:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فيما يخص الأطفال ممن تزيد أعمارهم عن شهرٍ واحدٍ والمراهقين، سيحدد الطبيب الجرعة. الجرعة القُصوى هي 4 مجم تُعطى في هيئة حَقْن بطيءٍ في الوريد. لأغراض الوقاية، ستُعطى هذه الجرعة قبل إجراء العملية الجراحية مباشرةً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المرضى المُصابون بمشاكل متوسطة أو شديدة في الكبد</strong></p><p dir="RTL">يجب ألا تزيد الجرعة اليومية الإجمالية عن 8 مجم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة استمرار شعورك بالإعياء أو استمرار الإعياء</strong></p><p dir="RTL">يجب أن يبدأ مفعول عقار زوفران للحقن في الظهور بعد الحَقْن بوقتٍ قصيرٍ. إذا استمرت إصابتك بالإعياء أو شعورك به، فأخبِر طبيبك أو الممرض(ة).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تلقيت كمية أكثر مما يجب من عقار زوفران للحقن</strong></p><p dir="RTL">سيتولى طبيبك أو الممرض(ة) إعطاءك أو إعطاء طفلك عقار زوفران للحقن؛ لذا فمن غير المُرجَّح أن تتلقى أو يتلقى طفلك كمية كبيرة للغاية. إذا اعتقدت أنه تم إعطاؤك أو إعطاء طفلك كمية كبيرة للغاية أو حدث إغفال لإحدى الجرعات، فأخبِر طبيبك أو الممرض(ة).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثله مثل جميع الأدوية، قد يُسبب عقار زوفران للحقن آثارًا جانبيةً، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تفاعلات الحساسية</strong></p><p dir="RTL">إذا كنت تُعاني من أحد تفاعلات الحساسية، فأخبِر طبيبك أو أحد أفراد الطاقم الطبي فورًا. قد تشمل العلامات ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة مفاجئة من أزيز الصدر وألم الصدر أو ضيق الصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورُّم الجفون أو الوجه أو الشفتين أو الفم أو اللسان.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفحًا جلديًّا -بقعًا حمراء أو كتلًا أسفل الجلد (شرى [أرتكاريا]) في أيِّ مكان على الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هبوطًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تتضمن الآثار الجانبية الأخرى ما يلي</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جدًّا </strong><strong>(</strong><strong>قد تُؤثر على أكثر من شخص واحد من بين كل </strong><strong>10 </strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداعًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة </strong><strong>(</strong><strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>10&nbsp;</strong><strong>أشخاص</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدفء أو احمرار الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إمساكًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حدوث تغيُّرات في نتائج اختبارات وظائف الكبد (إذا كنت تلقيت عقار زوفران للحقن مع دواء يُسمى سِيسْبلاتين، خلاف ذلك يكون هذا الأثر الجانبي غير شائع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تهيُّجًا واحمرارًا في موضع الحَقْن.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong><strong>(</strong><strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>100 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فُواقًا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدَّم، الأمر الذي قد يجعلك تشعر بالإغماء أو الدوخة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألمًا بالصدر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوبات تشنُّجية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حركات غير معتادة للجسم أو اهتزازه.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة </strong><strong>(</strong><strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>1000 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدّوخة أو الدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم وضوح الرؤية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابًا في النَّظْم القلبي (يُسبب في بعض الأحيان فقدانًا مفاجئًا للوعي).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة جدًّا </strong><strong>(</strong><strong>قد تُؤثر على ما يصل إلى شخص واحد من بين كل </strong><strong>10000 </strong><strong>شخص</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف الرؤية أو فقدان الرؤية المؤقت، حيث تعود الرؤية عادةً في غضون 20 دقيقة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أُصبت بأية آثار جانبية، فتحدَّث إلى طبيبك أو الصيدلي أو الممرض(ة). يشمل ذلك أية آثار جانبية مُحتمَلة، غير المُدرجة في هذه النَّشرة. يُمكِنك أيضًا الإبلاغ عن الآثار الجانبية بشكل مباشر عبر برنامج البطاقة الصفراء على الموقع الإلكتروني: www.mhra.gov.uk/yellowcard.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بإبلاغك عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفظ هذا الدَّواء بعيدًا عن رؤية ومُتناوَل الأطفال.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم عقار زوفران للحقن بعد تاريخ انتهاء الصلاحية المدون على العبوة بعد كلمة &quot;EXP&quot;. يُشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يُحفَظ عقار زوفران للحقن في درجة حرارة أقل من 30 درجة مئوية. يُحفَظ بعيدًا عن الضوء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عند تخفيف عقار زوفران للحقن في السَّوائل الوريدية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب حفظه في درجة حرارة تتراوح بين 2 و8 درجة مئوية لمدة لا تزيد عن 24 ساعة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا يلزم حمايته من الضوء أثناء التَّسريب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من أي أدوية عن طريق إلقائها في مياه الصَّرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التَّخلص من الأدوية التي لم تَعُد تستخدمها. ستُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هي محتويات عقار زوفران للحقن؟</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة هي أوندانسيترون. يحتوي كل أمبول بحجم 2 مللي لتر من عقار زوفران للحقن على 4 مجم من أوندانسيترون. يحتوي كل أمبول بحجم 4 مللي لترات من عقار زوفران للحقن على 8 مجم من أوندانسيترون.</p><p>المكونات الأخرى هي حمض الستريك (E330) وسترات الصوديوم (E331) وكلوريد الصوديوم وماء للحَقْن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&zwnj;أ.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ما هو شكل عقار زوفران للحقن؟ وما هي محتويات العبوة؟</strong></p><p dir="RTL">عقار زوفران للحقن عبارة عن سائل صافٍ عديم اللون. يتوفر عقار زوفران للحقن في هيئة:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمبولات زجاجية بحجم 2 مللي لتر (4 مجم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمبولات زجاجية بحجم 4 مللي لترات (8 مجم)</p><p dir="RTL">&nbsp;</p><p style="text-align:justify">يأتي مُعبأ في عبوات بها 5 أمبولات. لا يتم تسويق جميع العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق لهذا المنتج هي شركة نوفارتس فارما إيه جي.</strong></p><p><strong>www.Novartis.com</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ‌د.	آخر تاريخ اعتماد لهذه النَّشرة كان في 09/2020 من قبل الوكالة التنظيمية للأدوية ومنتجات الرعاية الصحية.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zofran® Injection 2 mg/ml
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zofran Injection 2 mg/ml: 2 ml glass ampoules each containing 4 mg ondansetron (as hydrochloride dihydrate) in aqueous solution for intramuscular or intravenous administration. 4 ml glass ampoules each containing 8 mg ondansetron (as hydrochloride dihydrate) in aqueous solution for intravenous or intramuscular administration.

Zofran Flexi-amp injection 2 mg/ml: 2 ml plastic ampoules each containing 4 mg ondansetron (as hydrochloride dihydrate) in aqueous solution for intramuscular or intravenous administration. 4 ml plastic ampoules each containing 8 mg ondansetron (as hydrochloride dihydrate) in aqueous solution for intravenous or intramuscular administration.

Excipient(s) with a known effect 
This product contains 7 mg of sodium per 4 mg dose (see section 4.4). For the full list of excipients see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Injection (aqueous solution).


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Adults:</u></em></p><p>Zofran is indicated for the management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. Zofran is indicated for the prevention and treatment of post-operative nausea and vomiting (PONV).</p><p>&nbsp;</p><p><em><u>Paediatric Population:</u></em></p><p>Zofran is indicated for the management of chemotherapy-induced nausea and vomiting (CINV) in children aged &ge;6 months, and for the prevention and treatment of PONV in children aged &ge;1 month</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>&nbsp;</p><p><u>C</u><u>hemotherapy and Radiotherapy induced nausea and vomiting (CINV and RINV)</u></p><p>&nbsp;</p><p><em>Adults:</em></p><p>The emetogenic potential of cancer treatment varies according to the doses and combinations of chemotherapy and radiotherapy regimens used. The route of administration and dose of Zofran should be flexible in the range of 8-32 mg a day and selected as shown below.</p><p>&nbsp;</p><p>&nbsp;</p><p><em>Emetogenic chemotherapy and radiotherapy: </em>Zofran can be given either by rectal, oral (tablets or syrup), intravenous or intramuscular administration.</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_2" o:spid="_x0000_s2050" style='position:absolute;left:0;
 text-align:left;margin-left:510.45pt;margin-top:20pt;width:2.75pt;height:.6pt;
 z-index:-251658240;mso-position-horizontal-relative:page' coordorigin="10209,400"
 coordsize="55,12" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Freeform_x0020_3" o:spid="_x0000_s2051" style='position:absolute;
  left:10209;top:400;width:55;height:12;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' coordsize="55,12" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" path="m,6r55,e" filled="f" strokeweight=".7pt">
  <v:path arrowok="t" o:connecttype="custom" o:connectlocs="0,406;55,406"
   o:connectangles="0,0"/>
 </v:shape><w:wrap anchorx="page"/>
</v:group><![endif]--><img width="5" height="2" src="file:///C:/Users/ahmedar2/AppData/Local/Temp/6/msohtmlclip1/01/clip_image001.gif" />For most patients receiving emetogenic chemotherapy or radiotherapy, the recommended intravenous (IV) dose of ondansetron is 8 mg and should be administered as a slow intravenous injection (in not less than 30 seconds) or intramuscular injection, immediately before treatment, followed by 8 mg orally twelve hourly.</p><p>&nbsp;</p><p>To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with</p><p>Zofran should be continued for up to 5 days after a course of treatment.</p><p>&nbsp;</p><p><em>H</em><em>i</em><em>ghly emetogenic chemotherapy</em>: For patients receiving highly emetogenic chemotherapy, e.g. high- dose cisplatin, Zofran can be given either by oral, rectal, intravenous or intramuscular administration. Zofran has been shown to be equally effective in the following dose schedules over the first 24 hours of chemotherapy:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A single dose of 8 mg by slow intravenous injection (in not less than 30 seconds) or intramuscular injection immediately before chemotherapy.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A dose of 8 mg by slow intravenous injection (in not less than 30 seconds) or intramuscular injection immediately before chemotherapy, followed by two further intravenous injection (in not less than 30 seconds) or intramuscular doses of 8 mg four hours apart, or by a constant infusion of</p><p>1 mg/hour for up to 24 hours.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A maximum initial intravenous dose of 16 mg diluted in 50-100 ml of saline or other compatible infusion fluid <em>(see section 6.6</em>) and infused over not less than 15 minutes immediately before chemotherapy. The initial dose of Zofran may be followed by two additional 8 mg intravenous doses (in not less than 30 seconds) or intramuscular doses four hours apart.</p><p>&nbsp;</p><p>A single dose greater than 16 mg must not be given due to dose dependent increase of QT- prolongation risk (see sections 4.4, 4.8 and 5.1).</p><p>&nbsp;</p><p>The selection of dose regimen should be determined by the severity of the emetogenic challenge. The efficacy of Zofran in highly emetogenic chemotherapy may be enhanced by the addition of a</p><p>single intravenous dose of dexamethasone sodium phosphate, 20 mg administered prior to</p><p>chemotherapy.</p><p>&nbsp;</p><p>To protect against delayed or prolonged emesis after the first 24 hours, oral or rectal treatment with</p><p>Zofran should be continued for up to 5 days after a course of treatment.</p><p>&nbsp;</p><p><em><u>P</u></em><em><u>aediatric Population:</u></em></p><p>&nbsp;</p><p><em>C</em><em>I</em><em>N</em><em>V in children and adolescents (aged 6 months to 17 years)</em></p><p>The dose for CINV can be calculated based on body surface area (BSA) or weight &ndash; see below. In paediatric clinical studies, ondansetron was given by IV infusion diluted in 25 to 50 ml of saline or other compatible infusion fluid and infused over not less than 15 minutes.</p><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing (sections</p><p>4.4.and 5.1).</p><p>&nbsp;</p><p>Zofran injection should be diluted in 5% dextrose or 0.9% sodium chloride or other compatible infusion fluid (see section 6.6) and infused intravenously over not less than 15 minutes.</p><p>&nbsp;</p><p>&nbsp;</p><p>There are no data from controlled clinical trials on the use of Zofran in the prevention of delayed or prolonged CINV. There are no data from controlled clinical trials on the use of Zofran for radiotherapy-induced nausea and vomiting in children.</p><p>&nbsp;</p><p><u>D</u><u>osing by BSA</u></p><p>Zofran should be administered immediately before chemotherapy as a single intravenous dose of</p><p>5 mg/m<sup>2</sup>. The single intravenous dose must not exceed 8 mg.</p><p>&nbsp;</p><p>Oral dosing can commence 12 hours later and may be continued for up to 5 days (Table 1).</p><p>&nbsp;</p><p>The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p><u>T</u><u>able 1: BSA-based dosing for CINV (aged &ge;6 months to 17 years)</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>BSA</p></td><td style="vertical-align:top"><p>Day 1 <sup>(a,b)</sup></p></td><td style="vertical-align:top"><p>Days 2-6 <sup>(b)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&lt; 0.6 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup>&nbsp;IV plus</p><p>2 mg syrup after 12 hrs</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hrs</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 0.6 m<sup>2</sup> to &le; 1.2 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup>&nbsp;IV plus</p><p>4 mg syrup or tablet after 12 hrs</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every</p><p>12 hrs</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 1.2 m<sup>2</sup></p></td><td style="vertical-align:top"><p>5 mg/m<sup>2</sup>&nbsp;or 8 mg IV plus 8 mg</p><p>syrup or tablet after 12 hours</p></td><td style="vertical-align:top"><p>8 mg syrup or tablet every</p><p>12 hours</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The intravenous dose must not exceed 8 mg.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg</p><p>&nbsp;</p><p>Dosing by bodyweight</p><p>Weight-based dosing results in higher total daily doses compared to BSA-based dosing (sections 4.4. and 5.1).</p><p>Zofran should be administered immediately before chemotherapy as a single intravenous dose of</p><p>0.15 mg/kg. The single intravenous dose must not exceed 8 mg. Two further intravenous doses may be given in 4-hourly intervals.</p><p>&nbsp;</p><p>Oral dosing can commence 12 hours later and may be continued for up to 5 days (Table 2).</p><p>&nbsp;</p><p>The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p><u>T</u><u>able 2: Weight-based dosing for CINV (aged &ge; 6 months to 17 years)</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Body Weight</p></td><td style="vertical-align:top"><p>Day 1 <sup>(a,b)</sup></p></td><td style="vertical-align:top"><p>Days 2-6 <sup>(b)</sup></p></td></tr><tr><td style="vertical-align:top"><p>&le; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg IV</p><p>every 4 hrs</p></td><td style="vertical-align:top"><p>2 mg syrup every 12 hrs</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 10 kg</p></td><td style="vertical-align:top"><p>Up to 3 doses of 0.15 mg/kg IV</p><p>every 4 hrs</p></td><td style="vertical-align:top"><p>4 mg syrup or tablet every</p><p>12 hrs</p></td></tr></tbody></table><p>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The intravenous dose must not exceed 8 mg.</p><p>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The total dose over 24 hours (given as divided doses) must not exceed adult dose of 32 mg.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>In patients 65 to 74 years of age, the dose schedule for adults can be followed. All intravenous doses should be diluted in 50-100 ml of saline or other compatible infusion fluid (see section 6.6) and</p><p>infused over 15 minutes.</p><p>&nbsp;</p><p>In patients 75 years of age or older, the initial intravenous dose of Zofran should not exceed 8 mg. All intravenous doses should be diluted in 50-100 ml of saline or other compatible infusion fluid (see section 6.6) and infused over 15 minutes. The initial dose of 8 mg may be followed by two further intravenous doses of 8 mg, infused over 15 minutes and given no less than four hours apart. (see section 5.2)</p><p>&nbsp;</p><p><em>Patients with Renal Impairment</em></p><p>No alteration of daily dosage or frequency of dosing, or route of administration are required.</p><p>&nbsp;</p><p><em>Patients with Hepatic Impairment</em></p><p>Clearance of Zofran is significantly reduced and serum half-life significantly prolonged in subjects with moderate or severe impairment of hepatic function. In such patients a total daily dose of 8 mg should not be exceeded and therefore parenteral or oral administration is recommended.</p><p>&nbsp;</p><p><em>Patients with Poor Sparteine/Debrisoquine Metabolism</em></p><p>The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure levels no different from those of the general population. No alteration of daily dosage or frequency of dosing is required.</p><p>&nbsp;</p><p><u>Post-operative nausea and vomiting (PONV):</u></p><p>&nbsp;</p><p><em>Adults</em></p><p>For the prevention of PONV, ondasetron can be administered orally or by intravenous or intramuscular injection.</p><p>&nbsp;</p><p>The recommended dose is as a single dose of 4 mg given by intramuscular or slow intravenous injection at induction of anaesthesia.</p><p>&nbsp;</p><p>For treatment of established PONV, A single dose of 4 mg given by intramuscular or slow intravenous injection is recommended.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>&nbsp;</p><p><u>PONV in children and adolescents (aged 1 month to 17 years)</u></p><p>&nbsp;</p><p>For prevention of PONV in paediatric patients having surgery performed under general anaesthesia, a single dose of Zofran may be administered by slow intravenous injection (not less than 30 seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg either prior to, at or after induction of anaesthesia.</p><p>&nbsp;</p><p>For the treatment of PONV after surgery in paediatric patients having surgery performed under general anaesthesia, a single dose of Zofran may be administered by slow intravenous injection (not less than</p><p>30 seconds) at a dose of 0.1 mg/kg up to a maximum of 4 mg.</p><p>&nbsp;</p><p>There are no data on the use of Zofran in the treatment of PONV in children below 2 years of age.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>There is limited experience in the use of Zofran in the prevention and treatment of PONV in the elderly, however Zofran is well tolerated in patients over 65 years receiving chemotherapy.</p><p>&nbsp;</p><p><em>P</em><em>atients with Renal Impairment</em></p><p>No alteration of daily dosage or frequency of dosing, or route of administration are required.</p><p>&nbsp;</p><p><em>P</em><em>atients with Hepatic Impairment</em></p><p>Clearance of Zofran is significantly reduced and serum half life significantly prolonged in subjects with moderate or severe impairment of hepatic function.&nbsp; In such patients a total daily dose of 8 mg</p><p>should not be exceeded and therefore parenteral or oral administration is recommended.</p><p>&nbsp;</p><p><em>Patients with poor Sparteine/Debrisoquine Metabolism</em></p><p>The elimination half-life of ondansetron is not altered in subjects classified as poor metabolisers of sparteine and debrisoquine. Consequently in such patients repeat dosing will give drug exposure levels</p><p>no different from those of the general population. No alteration of daily dosage or frequency of dosing are required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Concomitant use with apomorphine is contraindicated (see section 4.5 interactions). 


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5HT3 receptor antagonists.</p><p>&nbsp;</p><p>Respiratory events should be treated symptomatically and clinicians should pay particular attention to them as precursors of hypersensitivity reactions.</p><p>&nbsp;</p><p>Ondansetron prolongs the QT interval in a dose-dependent manner (see section 5.1). In addition, post- marketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron in patients with congenital long QT syndrome. Ondansetron should be administered with caution to patients who have or may develop prolongation of QTc, including patients with electrolyte abnormalities, congestive heart failure, bradyarrhythmias or patients taking other medicinal products that lead to QT prolongation or electrolyte abnormalities.</p><p>&nbsp;</p><p>Hypokalaemia and hypomagnesaemia should be corrected prior to ondansetron administration.</p><p>&nbsp;</p><p>There have been post-marketing reports describing patients with serotonin syndrome (including</p><p>altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRI) and serotonin noradrenaline reuptake inhibitors (SNRIs) (see section 4.5). If concomitant treatment with ondansetron and other serotonergic drugs is clinically warranted, appropriate observation of the patient is advised.</p><p>&nbsp;</p><p>As ondansetron is known to increase large bowel transit time, patients with signs of sub-acute intestinal obstruction should be monitored following administration.</p><p>&nbsp;</p><p>In patients with adenotonsillar surgery prevention of nausea and vomiting with ondansetron may mask occult bleeding. Therefore, such patients should be followed carefully after ondansetron.</p><p>&nbsp;</p><p>Zofran Injection contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &ldquo;sodium-free&rdquo;.</p><p>&nbsp;</p><p><em>Paediatric Population</em></p><p>Paediatric patients receiving ondansetron with hepatotoxic chemotherapeutic agents should be monitored closely for impaired hepatic function.</p><p>&nbsp;</p><p><u>C</u><u>I</u><u>N</u><u>V</u><u>: </u>When calculating the dose on an mg/kg basis and administering three doses at 4-hour intervals, the total daily dose will be higher than if one single dose of 5 mg/m<sup>2</sup> followed by an oral dose is given. The comparative efficacy of these two different dosing regimens has not been investigated in clinical trials. Cross-trial comparison indicates similar efficacy for both regimens (section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence that ondansetron either induces or inhibits the metabolism of other drugs commonly co-administered with it. Specific studies have shown that there are no interactions when ondansetron is administered with alcohol, temazepam, furosemide, alfentanil, tramadol, morphine, lidocaine, thiopental, or propofol.</p><p>&nbsp;</p><p>Ondansetron is metabolised by multiple hepatic cytochrome P-450 enzymes: CYP3A4, CYP2D6 and CYP1A2. Due to the multiplicity of metabolic enzymes capable of metabolising ondansetron, enzyme inhibition or reduced activity of one enzyme (e.g. CYP2D6 genetic deficiency) is normally compensated by other enzymes and should result in little or no significant change in overall ondansetron clearance or dose requirement.</p><p>&nbsp;</p><p>Caution should be exercised when ondansetron is coadministered with drugs that prolong the QT</p><p>interval and/or cause electrolyte abnormalities. (See section 4.4).</p><p>&nbsp;</p><p>Use of ondansetron with QT prolonging drugs may result in additional QT prolongation. Concomitant use of ondansetron with cardiotoxic drugs (e.g. anthracyclines (such as doxorubicin, daunorubicin) or trastuzumab), antibiotics (such as erythromycin), antifungals (such as ketoconazole), antiarrhythmics (such as amiodarone) and beta blockers (such as atenolol or timolol) may increase the risk of arrhythmias. (See section 4.4).</p><p>&nbsp;</p><p><em>Serotonergic Drugs (e.g. SSRIs and SNRIs): </em>There have been post-marketing reports describing patients with serotonin syndrome (including altered mental status, autonomic instability and neuromuscular abnormalities) following the concomitant use of ondansetron and other serotonergic drugs (including SSRIs and SNRIs). (See section 4.4)</p><p>&nbsp;</p><p><em>Apomorphine: </em>Based on reports of profound hypotension and loss of consciousness when ondansetron was administered with apomorphine hydrochloride, concomitant use with apomorphine is contraindicated.</p><p>&nbsp;</p><p><em>Phenytoin, Carbamazepine and Rifampicin: </em>In patients treated with potent inducers of CYP3A4 (i.e. phenytoin, carbamazepine, and rifampicin), the oral clearance of ondansetron was increased and ondansetron blood concentrations were decreased.</p><p>&nbsp;</p><p><em>Tramadol: </em>Data from small studies indicate that ondansetron may reduce the analgesic effect of tramadol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential </u></p><p>Women of childbearing potential should consider the use of contraception.</p><p><u>&nbsp;</u></p><p><u>Pregnancy</u></p><p>Based on human experience from epidemiological studies, ondansetron is suspected to cause orofacial malformations when administered during the first trimester of pregnancy.</p><p>In one cohort study including 1.8 million pregnancies, first trimester ondansetron use was associated with an increased risk of oral clefts (3 additional cases per 10 000 women treated; adjusted relative risk, 1.24, (95% CI 1.03-1.48)).</p><p>The available epidemiological studies on cardiac malformations show conflicting results.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p>Ondansetron should not be used during the first trimester of pregnancy.</p><p>&nbsp;</p><p><u>B</u><u>r</u><u>east-feeding</u></p><p>Tests have shown that ondansetron passes into the milk of lactating animals. It is therefore recommended that mothers receiving Zofran should not breast-feed their babies.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There is no information on the effects of ondansetron on human fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zofran has no or negligible influence on the ability to drive and use machines.</p><p>In psychomotor testing ondansetron does not impair performance nor cause sedation. No detrimental effects on such activities are predicted from the pharmacology of ondansetron.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tabulated list of adverse reactions</u></p><p>Adverse events are listed below by system organ class and frequency.&nbsp; Frequencies are defined as:</p><p>very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000 to</p><p>&lt;1/1000) and very rare (&lt;1/10,000). Very common, common and uncommon events were generally determined from clinical trial data. The incidence in placebo was taken into account.&nbsp; Rare and very rare events were generally determined from post-marketing spontaneous data.</p><p>&nbsp;</p><p>The following frequencies are estimated at the standard recommended doses of ondansetron. The adverse event profiles in children and adolescents were comparable to that seen in adults.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="2" style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Immediate hypersensitivity reactions sometimes severe, including anaphylaxis.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Very common:</p></td><td style="vertical-align:top"><p>Headache.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Seizures, movement disorders (including extrapyramidal reactions such as dystonic reactions, oculogyric crisis and dyskinesia)<sup>(1)</sup>.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Dizziness predominantly during rapid IV administration.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>Transient visual disturbances (e.g. blurred vision) predominantly during IV administration.</p></td></tr><tr><td style="vertical-align:top"><p>Very rare:</p></td><td style="vertical-align:top"><p>Transient blindness predominantly during IV administration <sup>(2)</sup>.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Arrhythmias, chest pain with or without ST segment depression, bradycardia.</p></td></tr><tr><td style="vertical-align:top"><p>Rare:</p></td><td style="vertical-align:top"><p>QTc prolongation (including Torsade de Pointes).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Sensation of warmth or flushing.</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Hypotension.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>&nbsp;Hiccups.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Constipation</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Uncommon:</p></td><td style="vertical-align:top"><p>Asymptomatic increases in liver function tests <sup>(3)</sup>.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>G</strong><strong>eneral disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Common:</p></td><td style="vertical-align:top"><p>Local IV injection site reactions.</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>1.&nbsp; &nbsp;Observed without definitive evidence of persistent clinical sequelae.</p><p>2.&nbsp; &nbsp;The majority of the blindness cases reported resolved within 20 minutes. Most patients had received chemotherapeutic agents, which included cisplatin. Some cases of transient blindness were reported as cortical in origin.</p><p>3.&nbsp; &nbsp;These events were observed commonly in patients receiving chemotherapy with cisplatin.</p></td></tr></tbody></table><p>&nbsp;</p><p><u>R</u><u>eporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>&nbsp;</p><p><strong>-<em>To reports any side effect(s): </em></strong></p><p>&middot;&nbsp;&nbsp;&nbsp; <strong><em>Saudi Arabia: </em></strong></p><p>Saudi Food and Drug Authority National Pharmacovigilance Center (NPC):</p><p>o Fax: +966112057662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2340.</p><p>o Toll free phone: 8002490000</p><p>o SFDA call center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p><p>Patient Safety Department Novartis Consulting AG - Saudi Arabia:</p><p>o Toll Free Number: 8001240078</p><p>o Phone: +996112658100</p><p>o Fax: +966112658107</p><p>o Email: adverse.events@novartis.com&nbsp;</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp; Other GCC States:</p><p>-&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and Signs</u></p><p>There is limited experience of ondansetron overdose. In the majority of cases, symptoms were similar to those already reported in patients receiving recommended doses (see section 4.8). Manifestations</p><p>that have been reported include visual disturbances, severe constipation, hypotension and a vasovagal</p><p>episode with transient second-degree AV block.</p><p>&nbsp;</p><p>Ondansetron prolongs the QT interval in a dose-dependent fashion. ECG monitoring is recommended in cases of overdose.</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>Paediatric cases consistent with serotonin syndrome have been reported after inadvertent oral overdoses of ondansetron (exceeded estimated ingestion of 4 mg/kg) in infants and children aged 12 months to 2 years.</p><p>&nbsp;</p><p><u>Management</u></p><p>There is no specific antidote for ondansetron, therefore in all cases of suspected overdose, symptomatic and supportive therapy should be given as appropriate.</p><p>&nbsp;</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p><p>&nbsp;</p><p>The use of ipecacuanha to treat overdose with ondansetron is not recommended, as patients are unlikely to respond due to the anti-emetic action of ondansetron itself.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Serotonin (5HT3) antagonist, ATC code: A04AA01</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Ondansetron is a potent, highly selective 5HT3 receptor-antagonist. Its precise mode of action in the control of nausea and vomiting is not known. Chemotherapeutic agents and radiotherapy may cause release of 5HT in the small intestine initiating a vomiting reflex by activating vagal afferents via 5HT3 receptors. Ondansetron blocks the initiation of this reflex. Activation of vagal afferents may also cause a release of 5HT in the area postrema, located on the floor of the fourth ventricle, and this may also promote emesis through a central mechanism. Thus, the effect of ondansetron in the management of</p><p>the nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy is probably due to antagonism of 5HT3 receptors on neurons located both in the peripheral and central nervous system.</p><p>&nbsp;</p><p>The mechanisms of action in post-operative nausea and vomiting are not known but there may be common pathways with cytotoxic induced nausea and vomiting.</p><p>&nbsp;</p><p>Ondansetron does not alter plasma prolactin concentrations.</p><p>&nbsp;</p><p><u>Clinical safety and efficacy</u></p><p>The role of ondansetron in opiate-induced emesis is not yet established.</p><p>&nbsp;</p><p><u>Q</u><u>T Prolongation</u></p><p>The effect of ondansetron on the QTc interval was evaluated in a double blind, randomised, placebo and positive (moxifloxacin) controlled, crossover study in 58 healthy adult men and women.</p><p>Ondansetron doses included 8 mg and 32 mg infused intravenously over 15 minutes. At the highest</p><p>tested dose of 32 mg, the maximum mean (upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 19.6 (21.5) msec. At the lower tested dose of 8 mg, the maximum mean</p><p>(upper limit of 90% CI) difference in QTcF from placebo after baseline-correction was 5.8 (7.8) msec.</p><p>In this study, there were no QTcF measurements greater than 480 msec and no QTcF prolongation was greater than 60 msec. No significant changes were seen in the measured electrocardiographic PR or QRS intervals.</p><p>&nbsp;</p><p>Paediatric population</p><p>&nbsp;</p><p><u>C</u><u>I</u><u>N</u><u>V</u></p><p>The efficacy of ondansetron in the control of emesis and nausea induced by cancer chemotherapy was assessed in a double-blind randomised trial in 415 patients aged 1 to 18 years (S3AB3006). On the days of chemotherapy, patients received either ondansetron 5 mg/m<sup>2</sup> intravenous and ondansetron</p><p>4 mg orally after 8 to 12 hours or ondansetron 0.45 mg/kg intravenous and placebo orally after 8 to</p><p>12 hours. Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. Complete control of emesis on worst day of chemotherapy was 49% (5 mg/m<sup>2</sup> intravenous and ondansetron 4 mg orally) and 41% (0.45 mg/kg intravenous and placebo orally). Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 3 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>&nbsp;</p><p>A double-blind randomised placebo-controlled trial (S3AB4003) in 438 patients aged 1 to 17 years demonstrated complete control of emesis on worst day of chemotherapy in:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 73% of patients when ondansetron was administered intravenously at a dose of 5 mg/m<sup>2</sup></p><p>intravenous together with 2 to 4 mg dexamethasone orally</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 71% of patients when ondansetron was administered as syrup at a dose of 8 mg together with 2 to</p><p>4 mg dexamethasone orally on the days of chemotherapy.</p><p>&nbsp;</p><p>Post-chemotherapy both groups received 4 mg ondansetron syrup twice daily for 2 days. There was no difference in the overall incidence or nature of adverse events between the two treatment groups.</p><p>&nbsp;</p><p>The efficacy of ondansetron in 75 children aged 6 to 48 months was investigated in an open-label, non-comparative, single-arm study (S3A40320). All children received three 0.15 mg/kg doses of intravenous ondansetron, administered 30 minutes before the start of chemotherapy and then at 4 and 8 hours after the first dose. Complete control of emesis was achieved in 56% of patients.</p><p>&nbsp;</p><p>Another open-label, non-comparative, single-arm study (S3A239) investigated the efficacy of one intravenous dose of 0.15 mg/kg ondansetron followed by two oral ondansetron doses of 4 mg for children aged &lt; 12 years and 8 mg for children aged &ge; 12 years (total no. of children n = 28). Complete control of emesis was achieved in 42% of patients.</p><p>&nbsp;</p><p><u>PONV</u></p><p>The efficacy of a single dose of ondansetron in the prevention of post-operative nausea and vomiting was investigated in a randomised, double-blind, placebo-controlled study in 670 children aged 1 to 24 months (post-conceptual age &ge;44 weeks, weight &ge; 3 kg). Included subjects were scheduled to undergo</p><p>elective surgery under general anaesthesia and had an ASA status &le; III. A single dose of ondansetron</p><p>0.1 mg/kg was administered within five minutes following induction of anaesthesia. The proportion of subjects who experienced at least one emetic episode during the 24-hour assessment period (ITT) was greater for patients on placebo than those receiving ondansetron (28% vs. 11%, p &lt;0.0001).</p><p>&nbsp;</p><p>Four double-blind, placebo-controlled studies have been performed in 1469 male and female patients (2 to 12 years of age) undergoing general anaesthesia. Patients were randomised to either single intravenous doses of ondansetron (0.1 mg/kg for paediatric patients weighing 40 kg or less, 4 mg for paediatric patients weighing more than 40 kg; number of patients = 735) or placebo (number of patients = 734). Study drug was administered over at least 30 seconds, immediately prior to or following anaesthesia induction. Ondansetron was significantly more effective than placebo in preventing nausea and vomiting. The results of these studies are summarised in Table 3.</p><p>&nbsp;</p><p><u>T</u><u>able 3: &nbsp;Prevention and treatment of PONV in Paediatric Patients &ndash; Treatment response over 24 hours</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Study</p></td><td style="vertical-align:top"><p>Endpoint</p></td><td style="vertical-align:top"><p>Ondansetron %</p></td><td style="vertical-align:top"><p>Placebo %</p></td><td style="vertical-align:top"><p>p value</p></td></tr><tr><td style="vertical-align:top"><p>S3A380</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>68</p></td><td style="vertical-align:top"><p>39</p></td><td style="vertical-align:top"><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT09</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>61</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3A381</p></td><td style="vertical-align:top"><p>CR</p></td><td style="vertical-align:top"><p>53</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>&le;0.001</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no nausea</p></td><td style="vertical-align:top"><p>64</p></td><td style="vertical-align:top"><p>51</p></td><td style="vertical-align:top"><p>0.004</p></td></tr><tr><td style="vertical-align:top"><p>S3GT11</p></td><td style="vertical-align:top"><p>no emesis</p></td><td style="vertical-align:top"><p>60</p></td><td style="vertical-align:top"><p>47</p></td><td style="vertical-align:top"><p>0.004</p></td></tr></tbody></table><p>CR = no emetic episodes, rescue or withdrawal</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Following oral administration, ondansetron is passively and completely absorbed from the gastrointestinal tract and undergoes first pass metabolism. Peak plasma concentrations of about</p><p>30 ng/mL are attained approximately 1.5 hours after an 8 mg dose. For doses above 8 mg the increase</p><p>in ondansetron systemic exposure with dose is greater than proportional; this may reflect some reduction in first pass metabolism at higher oral doses. Mean bioavailability in healthy male subjects, following the oral administration of a single 8 mg tablet, is approximately 55 to 60%. Bioavailability, following oral administration, is slightly enhanced by the presence of food but unaffected by antacids. Studies in healthy elderly volunteers have shown slight, but clinically insignificant, age-related increases in both oral bioavailability (65%) and half-life (5 hours) of ondansetron.</p><p>&nbsp;</p><p>The disposition of ondansetron following oral, intramuscular and intravenous dosing in adults is similar with a terminal half life of about 3 hours and steady state volume of distribution of about</p><p>140 L. Equivalent systemic exposure is achieved after intramuscular and intravenous administration of ondansetron.</p><p>&nbsp;</p><p>A 4 mg intravenous infusion of ondansetron given over 5 minutes results in peak plasma concentrations of about 65 ng/ml. Following intramuscular administration of ondansetron, peak plasma concentrations of about 25 ng/ml are attained within 10 minutes of injection.</p><p>&nbsp;</p><p>Following administration of ondansetron suppository, plasma ondansetron concentrations become detectable between 15 and 60 minutes after dosing. Concentrations rise in an essentially linear fashion, until peak concentrations of 20-30 ng/ml are attained, typically 6 hours after dosing. Plasma concentrations then fall, but at a slower rate than observed following oral dosing due to continued absorption of ondansetron. The absolute bioavailability of ondansetron from the suppository is approximately 60% and is not affected by gender. The half life of the elimination phase following suppository administration is determined by the rate of ondansetron absorption, not systemic clearance</p><p>and is approximately 6 hours. Females show a small, clinically insignificant, increase in half-life in comparison with males.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Ondansetron is not highly protein bound (70-76%).</p><p>&nbsp;</p><p>Biotransformation and Elimination</p><p>Ondansetron is cleared from the systemic circulation predominantly by hepatic metabolism through multiple enzymatic pathways. Less than 5% of the absorbed dose is excreted unchanged in the urine. The absence of the enzyme CYP2D6 (the debrisoquine polymorphism) has no effect on ondansetron&#39;s pharmacokinetics. The pharmacokinetic properties of ondansetron are unchanged on repeat dosing.</p><p>&nbsp;</p><p><u>Special Patient Populations</u></p><p>&nbsp;</p><p><em>G</em><em>ender</em></p><p>&nbsp;</p><p>Gender differences were shown in the disposition of ondansetron, with females having a greater rate and extent of absorption following an oral dose and reduced systemic clearance and volume of distribution (adjusted for weight).</p><p>&nbsp;</p><p><em>C</em><em>hildren and Adolescents (aged 1 month to 17 years)</em></p><p>In paediatric patients aged 1 to 4 months (n = 19) undergoing surgery, weight normalised clearance was approximately 30% slower than in patients aged 5 to 24 months (n = 22) but comparable to the</p><p>patients aged 3 to 12 years. The half-life in the patient population aged 1 to 4 month was reported to</p><p>average 6.7 hours compared to 2.9 hours for patients in the 5 to 24 month and 3 to 12 year age range. The differences in pharmacokinetic parameters in the 1 to 4 month patient population can be explained in part by the higher percentage of total body water in neonates and infants and a higher volume of distribution for water soluble drugs like ondansetron.</p><p>&nbsp;</p><p>In paediatric patients aged 3 to 12 years undergoing elective surgery with general anaesthesia, the absolute values for both the clearance and volume of distribution of ondansetron were reduced in comparison to values with adult patients. Both parameters increased in a linear fashion with weight and by 12 years of age, the values were approaching those of young adults. When clearance and volume of distribution values were normalised by body weight, the values for these parameters were</p><p>similar between the different age group populations. Use of weight-based dosing compensates for age- related changes and is effective in normalising systemic exposure in paediatric patients.</p><p>&nbsp;</p><p>Population pharmacokinetic analysis was performed on 428 subjects (cancer patients, surgery patients and healthy volunteers) aged 1 month to 44 years following intravenous administration of ondansetron. Based on this analysis, systemic exposure (AUC) of ondansetron following oral or IV dosing in children and adolescents was comparable to adults, with the exception of infants aged 1 to</p><p>4 months. Volume was related to age and was lower in adults than in infants and children. Clearance was related to weight but not to age with the exception of infants aged 1 to 4 months. It is difficult to conclude whether there was an additional reduction in clearance related to age in infants 1 to 4 months or simply inherent variability due to the low number of subjects studied in this age group. Since patients less than 6 months of age will only receive a single dose in PONV a decreased clearance is</p><p>not likely to be clinically relevant.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Early Phase I studies in healthy elderly volunteers showed a slight age-related decrease in clearance, and an increase in half-life of ondansetron. However, wide inter-subject variability resulted in considerable overlap in pharmacokinetic parameters between young (&lt; 65 years of age) and elderly subjects (&ge; 65 years of age) and there were no overall differences in safety or efficacy observed between young and elderly cancer patients enrolled in CINV clinical trials to support a different dosing recommendation for the elderly.</p><p>&nbsp;</p><p>Based on more recent ondansetron plasma concentrations and exposure-response modelling, a greater effect on QTcF is predicted in patients &ge; 75 years of age compared to young adults. Specific dosing information is provided for patients over 65 years of age and over 75 years of age for IV dosing (see section 4.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In patients with renal impairment (creatinine clearance 15-60 ml/min), both systemic clearance and volume of distribution are reduced following IV administration of ondansetron, resulting in a slight, but clinically insignificant, increase in elimination half-life (5.4 hours). A study in patients with severe renal impairment who required regular haemodialysis (studied between dialyses) showed</p><p>ondansetron&#39;s pharmacokinetics to be essentially unchanged following intravenous administration.</p><p>&nbsp;</p><p><em>H</em><em>epatic impairment</em></p><p>Following oral, intravenous or intramuscular dosing in patients with severe hepatic impairment, ondansetron&#39;s systemic clearance is markedly reduced with prolonged elimination half-lives (15 to 32</p><p>hours) and an oral bioavailability approaching 100% due to reduced pre-systemic metabolism. The</p><p>pharmacokinetics of ondansetron following administration as a suppository have not been evaluated in patients with hepatic impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Embryo-fetal development studies in rats and rabbits, did not show evidence of harm to the fetus when ondansetron was administered during the period of organogenesisat &nbsp;approximately 6 and 24 times respectively the maximum recommended human oral dose of 24 mg/day, , based on body surface area. In a pre- and postnatal developmental toxicity study, there were no effects upon the pregnant rats and the pre- and postnatal development of their offspring, including reproductive performance at approximately 6 times the maximum recommended human oral dose of 24 mg/day based on body surface area.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Citric acid monohydrate</p><p>Sodium citrate</p><p>Sodium chloride</p><p>Water for Injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zofran injection should not be administered in the same syringe or infusion as any other medication. Ondansetron injection should only be mixed with those infusion solutions that are recommended</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months (unopened). 24 hours (dilutions stored 2 - 8ºC).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Protect from light.&nbsp; Store below 30&ordm;C.</p><p>&nbsp;</p><p>Dilutions of Zofran injection in compatible intravenous infusion fluids are stable under normal room lighting conditions or daylight for at least 24 hours, thus no protection from light is necessary while infusion takes place.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zofran Injection:&nbsp; Type I clear glass snap-ring ampoules.</p><p>&nbsp;</p><p>Zofran Flexi-amp injection: Polypropylene blow-fill-sealed ampoules with a twist-off top and overwrapped in a double foil blister.</p><p>&nbsp;</p><p>5 ampoules are packed in a carton.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zofran Injection and Zofran Flexi-amp injection should not be autoclaved. Compatibility with intravenous fluids</p><p>Zofran injection should only be mixed with those infusion solutions which are recommended:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sodium Chloride Intravenous Infusion BP 0.9%w/v</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Glucose Intravenous Infusion BP 5%w/v</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mannitol Intravenous Infusion BP 10%w/v</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ringers Intravenous Infusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potassium Chloride 0.3%w/v and Sodium Chloride 0.9%w/v Intravenous Infusion BP</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potassium Chloride 0.3%w/v and Glucose 5%w/v Intravenous Infusion BP</p><p>&nbsp;</p><p>In keeping with good pharmaceutical practice dilutions of Zofran injection in intravenous fluids should be prepared at the time of infusion or stored at 2-8&deg;C for no more than 24 hours before the start of administration.</p><p>&nbsp;</p><p>Compatibility studies have been undertaken in polyvinyl chloride infusion bags and polyvinyl chloride administration sets. It is considered that adequate stability would also be conferred by the use of polyethylene infusion bags or Type 1 glass bottles.&nbsp; Dilutions of Zofran in sodium chloride 0.9%w/v or in glucose 5%w/v have been demonstrated to be stable in polypropylene syringes. It is considered that Zofran injection diluted with other compatible infusion fluids would be stable in polypropylene syringes.</p><p>&nbsp;</p><p><em>Compatibility with other drugs: </em>Zofran may be administered by intravenous infusion at 1 mg/hour,</p><p>e.g. from an infusion bag or syringe pump. The following drugs may be administered via the Y-site of the Zofran giving set for ondansetron concentrations of 16 to 160 micrograms/ml (e.g. 8 mg/500 ml and 8 mg/50 ml respectively);</p><p>&nbsp;</p><p><em>Cisplatin: </em>Concentrations up to 0.48 mg/ml (e.g. 240 mg in 500 mL) administered over one to eight hours.</p><p>&nbsp;</p><p><em>5-Fluorouracil: </em>Concentrations up to 0.8 mg/ml (e.g. 2.4 g in 3 litres or 400 mg in 500 ml) administered at a rate of at least 20 ml per hour (500 mL per 24 hours).&nbsp; Higher concentrations of</p><p>5-fluorouracil may cause precipitation of ondansetron. The 5-fluorouracil infusion may contain up to 0.045% w/v magnesium chloride in addition to other excipients shown to be compatible.</p><p>&nbsp;</p><p><em>Carboplatin: </em>Concentrations in the range 0.18 mg/ml to 9.9 mg/ml (e.g. 90 mg in 500 ml to 990 mg in 100 mL), administered over ten minutes to one hour.</p><p>&nbsp;</p><p><em>Etoposide: </em>Concentrations in the range 0.14 mg/ml to 0.25 mg/ml (e.g. 72 mg in 500 ml to 250 mg in 1 litre), administered over thirty minutes to one hour.</p><p>&nbsp;</p><p><em>Ceftazidime: </em>Doses in the range 250 mg to 2000 mg reconstituted with Water for Injections BP as recommended by the manufacturer (e.g. 2.5 ml for 250 mg and 10 ml for 2 g ceftazidime) and given as an intravenous bolus injection over approximately five minutes.</p><p>&nbsp;</p><p><em>Cyclophosphamide: </em>Doses in the range 100 mg to 1 g, reconstituted with Water for Injections BP,</p><p>5 ml per 100 mg cyclophosphamide, as recommended by the manufacturer and given as an intravenous bolus injection over approximately five minutes.</p><p>&nbsp;</p><p><em>Doxorubicin: </em>Doses in the range 10-100 mg reconstituted with Water for Injections BP, 5 ml per</p><p>10 mg doxorubicin, as recommended by the manufacturer and given as an intravenous bolus injection over approximately 5 minutes.</p><p>&nbsp;</p><p><em>Dexamethasone: </em>Dexamethasone sodium phosphate 20 mg may be administered as a slow intravenous injection over 2-5 minutes via the Y-site of an infusion set delivering 8 or 16 mg of ondansetron diluted in 50-100 ml of a compatible infusion fluid over approximately 15 minutes. Compatibility between dexamethasone sodium phosphate and ondansetron has been demonstrated supporting administration of these drugs through the same giving set resulting in concentrations in line of</p><p>32 microgram - 2.5 mg/ml for dexamethasone sodium phosphate and 8 microgram - 1 mg/ml for ondansetron.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The Marketing Authorization Holder for this Product is Novartis Pharma.
www.Novartis.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                This leaflet was last approved in 09/2020 by MHRA.
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>